Abstract
This article raises questions about the morality and value of experiments conducted mainly on psychiatric patient-subjects whose mental capacity and judgment are often impaired, making them incapable of giving informed consent. Its focus is on experimental studies in which psychotic symptoms in patients with schizophrenia have been knowingly exacerbated by suddenly withdrawing medications that they needed, administering known psychosis-producing substance such as L-dopa and apomorphine, and ignoring the treatment needs of those serving as experimental controls in placebo studies. Concerns are raised about the draft “Statement of Principles for Ethical Conduct” by the American College of Neuropsychopharmacology. Questions are also raised about the adequancy of current safeguards, including federal regulations, peer review, and the trivialization of “informed consent” by institutional review boards that operate under veils of secrecy. Implications for mental health policy are discussed, and suggestions are made for improving safeguards and reducing risks.
Similar content being viewed by others
References
Katz J: “Ethics and clinical research” revisited: A tribute to Henry K. Beecher.Hastings Center Report 1993; 25(5):31–39.
Annas GJ, Grodin MA (Eds.):The Nazi Doctors and the Nuremberg Code: Human Rights in Human Experimentation. New York: Oxford University Press, 1992.
Grodin MA: Historical origins of the Nuremberg Code. In: Annas GJ, Grodin MA (Eds.):The Nazi Doctors and the Nuremberg Code: Human Rights in Human Experimentation. New York: Oxford University Press, 1992, pp. 121–144.
Caplan AL: Are existing safeguards adequate?Journal of the California Alliance for the Mentally Ill 1994; 5(1):36–38.
Annas GJ: Experimentation and research.Journal of the California Alliance for the Mentally Ill 1994; 5(1): 9–11.
Annas GJ: The changing landscape of human experimentation: Nuremberg, Helsinki, and beyond.Health Matrix—Journal of Law and Medicine 1992; 2:119–140.
Declaration of Helsinki IV, World Medical Association, 18th World Medical Assembly, 1964; amended Hong Kong, September, 1989. Council for International Organizations of Medical Sciences (CIOMS), Geneva, 1993.
National Commission for the Protection of Human Subjects of Bimedical and Behavioral Research:Report and Recommendations: Research Involving Those Institutionalized as Mentally Infirm [The Belmont Report]. DHEW Pub. No. (05) 78-0006. Washington, DC: U.S. Department of Health, Education and Welfare, 1979.
45 Code of Federal Regulations (CFR) 46, 1985; revised 1991.
Agency says UCLA erred in medical experiments.Reuters, March 9, 1994.
Hilts PJ: Agency faults a UCLA study for suffering of mental patients.New York Times, March 10, 1994, p. A-1.
Garrett L: Closer tabs on human research urged.Newsday, March 11, 1994, p. A-17.
When the patient is also an experiment [Editorial].New York Times, March 14, 1994, p. A-16.
Horowitz J: For the sake of science.Los Angeles Times Magazine, September 11, 1994, pp. 16ff.
Subotnik KL, Neuchterlein KN: Prodromal signs and symptoms in schizophrenia relapse.Journal of Abnormal Psychology 1988; 97(4):405–412.
Office for Protection from Research Risks, Division of Human Subject Protections:Evaluation of Human Subject Protections in Schizophrenia Research Conducted by the University of California, Los Angeles, Washington, DC: U.S. Department of Health and Human Services, May 11, 1994.
Hawkins-Prince SL: Personal communication, December, 1994.
Thompson DI: Memorandum in opposition (on behalf of) Shalmah Lee Prince v. David L. Garver, M.D., et al., U.S. District Court, So. Dist. of Ohio, Western Division, October, 1995.
Becker JC: Amother's testimony.Journal of the California alliance for the Mentally Ill 1994; 5(1):17.
Davidson M, Keefe RSE, Mohs RC, et al.: L-dopa challenge and relapse in schizophrenia.American Journal of Psychiatry 1987; 144:934–938.
Department of Veterans Affairs, Bronx Medical Center: Consent forms for two-part-study: Neuroleptic withdrawal and Sinemet (L-dopa); obtained by author under FOIA [no date].
Davidson M: personal communciation, May 16, 1994.
Ogloff JRP, Otto RK: Are research participants truly informed? Readability of informed consent forms used in research.Ethics & Behavior 1991; 1(4):239–252.
Dorwart RA, Adler D, Berlant J, et al.: Taking issue: Outcomes assessment and psychiatric services.Hospital and Community Psychiatry 1994; 45(December):1165.
White KL:Healing the Schism: Epidemiology, Medicine and the Public's Health. New York: Springer-Verlag, 1991.
Pinel P:A Treatise on Insanity, David DD (Trans.). New York: Hafner, 1962.
Bockoven JS:Moral Treatment in American Psychiatry, New York: Springer, 1963.
Meyer A:Psychobiology: A Study of Man. Springfield, IL: Charles C Thomas, 1957.
Baruk H:Patients Are People Like Us: The Experiences of Half a Century in Neuropsychiatry. Finletter E, Ayer J (Trans.). New York: Morrow, 1978.
Lehrman NS: Effective psychotherapy in chronic schizophrenia.American Journal of Psychoanalysis 1982; 42: 121–132.
Lehrman NS: The bureaucratic destruction of patient’s faith in their doctors: Public psychiatry's negative lessons for general medicine.Bulletin of the New York Academy of Medicine 1994; 71:194–217.
Rothman KJ, Michels KB: The continuing unethical use of placebo controls.New England Journal of Medicine 1994: 331:394–398.
Jonas H: Philosophical reflections on experimenting with human subjects. In: Freund PA (Ed.):Experimentation with Human Subjects. New York: Braziler, 1969, pp. 1–31.
21 Code of Federal Regulations (CFR) ch. 1 (April 1, 1993 ed.): 314.126 (b) (2) (iv).
Beecher HK: Echics and clinical research.New England Journal of Medicine 1966; 274:1353–1360.
Destro RA: Law, professionalism, and bad attitude,Journal of the California Alliance for the Mentally Ill 1994;5(1):50–53.
Taubes G: Use of placebo controls in clinical trials disputed.Science 1991; 267:25–26.
Katz J: Human experimentation and human rights.Health Law Symposium: St. Louis University Law Journal 1993; 38(1):7–54.
Annas GJ:Judging medicine. Clifton, NJ: Humana, 1988, p. 331.
Herz MI, Hawkins LL, Liberman RP, et al.:Practice Guidelines for Treatment of Patients with Schizophrenia, Work Group on Schizophrenia. Draft 1A. Washington, DC: American Psychiatric Association, June 1994.
Hegarty JD, Baldessarini RJ, Tohen M, et al.: One hundred years of schizophrenia: A meta-analysis of the outcome literature.American Journal of Psychiatry 1994; 151:1409–1416.
Wyatt RJ: Neuroleptics and the natural course of schizophrenia.Schizophrenia Bulletin 1991; 17(2): 325–351.
Van Putten T: Why do schizophrenic patients refuse to take drugs?Archives of General Psychiatry 1974; 32:67–72.
Willwerth J: Tinkering with madness.Time, August 30, 1993, pp. 40–41.
Schizophrenic’s case spurs review of consent guidelines.Los Angeles Times, July 13, 1994, p. A-5.
Lehmann C: Family testimony reveals human dimension of UCLA schizophrenia research controversy.Psychiatric News, March 17, 1995, pp. 13–14.
Families tell their side of suicides.Santa Monica Outlook, August 13, 1995.
Shamoo AE, Irving DN: Accountability in research using persons with mental illness.Accountability in Research 1993; 3:1–17.
Sharav VH, Weisburd DE (Eds): Ethics in neurobiological research with human subjects [Special issue]. {jtJournal of the California Alliance for the Mentally Ill} {dy1994}; {vn5}({sn1}):1–69.
Shamoo AE: Our responsibility toward persons with mental illness as human subjects in research.Journal of the California Alliance for the Mentally Ill 1994; 5(1):14–16.
Shamoo AE, Keay TJ: Ethical concerns about replase studies.Cambridge Quarterly of Health Care Ethics 1996; 5:373–386.
Gilbert PL, Harris MJ, McAdams LA, et al.: Neuroleptic withdrawal in schizophrenic patients.Archives of General Psychiatry 1995; 52:173–186.
Baldessarini RJ, Viguera AC: Neuroleptic withdrawal in schizophrenic patients.Archives of General Psychiatry 1995; 52:189–191.
Ghaemi SN, Hundert EM: The ethics of research in mental illness.Journal of the California Alliance for the Mentally Ill 1994; 5(1):47–49.
Denber HCB: Tranquilizers in psychiatry. In: Freedman AM, Kaplan HI, Kaplan HS (eds.):Comprehensive textbook of psychiatry, Baltimore, MD: Williams & Wilkins, 1967, pp. 1251–1262.
Baldessarini RJ: Chemotherapy. In: Nicholi AM (Ed.):Harvard Guide to Modern Psychiatry. Cambridge, MA: Harvard University Press, 1978, pp. 387–432.
Breggin PR:Toxic Psychiatry: Why Therapy, Empathy, and Love Must Replace the Drugs, Electroshock, and Biochemical Theories of the “New Psychiatry” New York: St. Martin’s, 1991.
Jeste DV, Gilbert PL, McAdams LA, et al.: Considering neuroleptic maintenance and taper on a continuum.Archives of General Psychiatry 1995; 52:209–212.
Wolkin A, Angrist B, Wolf A, et al.: Effects of amphetamines on local cerebral metabolism in normal and schizophrenic subjects as determined by positive emission tomography,Psychopharmacology 1987; 92(2):241–246.
Daniel DG, Weinberger DG, Jones DW, et al.: The effect of amphetamine on regional cerebral blood flow during cognitive activation in schizophrenia.Journal of Neuroscience 1991; 11:1907–1917.
Szymanski S, Lieberman J, Pollack S, et al.: Clozapine effects on neuroendocrine responses to apomorphine challenge in chronic schizophrenia.Biological Psychiatry 1995; 37(1):52–55.
Wyatt RJ: Risks of withdrawing antipsychotic medications.Archives of General Psychiatry 1995; 52:205–208.
Greden JF, Tendon R: Long term treatment for lifetime disorders?Archives of General Psychiatry 1995; 52:197–200.
Opler LA: Conducting clinical psychiatric research in “non-research” settings.Journal of California Alliance for the Mentally Ill 1994; 5(1):30–31.
Irving DN: Psychiatric research: Reality check.Journal of the California Alliance for the Mentally Ill 1994 5 (1):42–44.
Katz J: Final reflections. In: Shamoo A (Ed.).Ethics in Neurobiological Research with Human Subjects, Buffalo, NY: Gordon Breach Science, 1996, pp. 331–337.
Klein DF, Schooler N: A statement of principles of ethical conduct for neuropsychopharmacologic research in human subjects. Draft revision, November 1995, American College of Neuropsychopharmacology.
Caplan A (eEd.):When Medicine Went Mad. totoa, NJ: Humana, 1992.
Wertham F:A Sign for Cain. London: Robert Hale, 1966.
Mitscherlich F, Mielke F:The Death Doctors, London: Elek, 1962.
Muller-Hill B:Murderous Science. Oxford, UK: Oxford University Press, 1988.
Proctor RN:Racial Hygiene: Medicine under the Nazis Cambridge, MA: Harvard University Press, 1988.
Hilts PJ: Consensus on ethics in research is elusive.New York Times, January 15, 1995, p. 24.
Burd, S: Researchers, advocates for mental patients clash over U.S. rules.Chronicle of Higher Education, January 20, 1995, p. A29.
Horvitz LA: Ethics study focuses on mentally ill.Insight, March 27, 1995, pp. 14–17.
Lieberman JA: The moral imperatives of medical research in human subjects.Journal of the California Alliance for the Mentally Ill 1994; 5(1):40–41.
Goodwin FK: Questions and answers.Journal of the California Alliance for the Mentally Ill 1994; 5(1): 45–47.
Van Kammen DP, Kelley ME, Gurklis JA, et al.: Behavioral vs. biochemical prediction of clinical stability following haloperidol withdrawal in schizophrenia.Archives of General Psychiatry 1995; 52:673–678.
This month in AGP.Archives of General Psychiatry 1995; 52:619.
Lehrman NS: Astate hospital population five years after admission: A yardstick for evaluative comparison of follow-up studies.Psychiatric Quarterly 1960; 34:658–681.
Rachlin HL, Goldman GS, Gurvitz M, et al.: Follow-up study of 317 patients discharged from Hillside Hospital in 1950.Journal of the Hillside Hospital 1956; 5:17–25.
Lehrman NS: Follow-up of brief and prolonged psychiatric hospitalization.Comprehensive Psychiatry 1961; 2: 227–240.
Angrist B: Ethical issues regarding prospective studies of amphetamine psychosis.Journal of the California Alliance for the Mentally Ill 1994; 5(1):32–33.
T.D. vNYS OMH, 626 N.Y.S. 2d 1015 (Sup. Ct. NYCnty 1995); Court order: Docket Order 5136/91 (Sup. Ct. NY Cnty) 3/20/95.
Hilts PJ: Judge tells health department to stop experiments on patients.New York Times, March 26, 1995, p. A-13.
Two courts put limits on research involving the mentally ill.Chronicle of Higher Education, March 31, 1995, p. A-27.
T.D. v. NYS OMH: Appellate Div. Order: Docket No. M-3213, 8/3/95; Appellate Div. [no docket no.] order denying motion to vacate, 1/29/96.
Lowenkron R, Zucker C: Court orders state to cease dangerous experiments on psychiatric patients. Press release, January 22, 1996, New York Lawyers for the Public Interest.
Mooney M: Halts drug testing on mental patients.Daily News, January 24, 1996, p. 12.
Thomasma, DC: Obtaining consent for research in the neurobiologically impaired.Journal of the California Alliance for the Mentally Ill 1994; 5(1):54–55.
Willwerth J: Madness in fine print.Time, November 7, 1994, p. 63.
Weinstein, HM:Psychiatry and the CIA: Victims of mind control. Washington, DC: APA, 1990.
Rubenstein LS: Psychiatric experimentation: The lessons of history,Journal of the California Alliance for the Mentally Ill 1994; 5(1):22–24.
Hilchey T: Dr. James Watts, 90, pioneer in use of frontal lobotomy [Obituary].New York Times, November 11, 1994, p. B-7.
Wong D: Neuropsychiatric hospital on probation.Daily Bruin, April 18, 1995, p. 1.
Shuit DP: Three top officials will leave UCLA clinic.Los Angeles Times, April 19, 1995, pp. B-1, B-4.
Hilts PJ: House panel told of more tests done without consent.New York Times, May 24, 1994, p. A-13.
President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research:Summing up. Washington DC: Government Printing Office, 1983.
Appelbaum P, Lidz C, Meisel A:Informed consent—legal theory and clinical practice, Oxford, UK: Oxford University Press, 1987.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Lehrman, N.S., Sharav, V.H. Ethical problems in psychiatric research. The Journal of Mental Health Administration 24, 227–250 (1997). https://doi.org/10.1007/BF02898516
Issue Date:
DOI: https://doi.org/10.1007/BF02898516